Here, we show that KRASG12C inhibition is associated with potent inhibition of ERK signaling but less potent and variable inhibition of PI3K/mTOR signaling, and that the sensitivity of tumor cell lines to KRASG12C inhibition is closely correlated with their ability to inhibit mTOR substrate phosphorylation. The gene discussed is MTOR; the disease is neoplasm.